| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: CIPH |
| Security Type |
Common Stock |
| Lead Underwriter |
SG Cowen Securities Corp |
| Days In Registration |
192 |
| Date Filed |
20-Mar-2000 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Biotechnology company dedicated to the discovery, development and commercialization of novel, high-value molecular diagnostic tests to help physicians diagnose, select appropriate treatments and improve outcomes for patients |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
25.63M |
| President and CEO |
William E. Rich, Ph.D |
| Number of Employees |
95 |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
825.0K |
| File Amount |
- |
| File Price Range |
$16.00 - $14.00 |
| File Mid Price |
$15.00 |
Current Filing Information
(Amended 28-Sep-2000) |
|
US |
|
Shares Filed |
5.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
5.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$75.0M |
| · % Change from Original |
|
| File Price Range |
$16.00 - $14.00 |
| File Mid Price |
$15.00 |
|
